Rize Oncology Inc.
RZONF
$0.16
$0.1639,900.00%
OTC PK
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -8.62% | 1.18% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 51.33% | 50.06% | |||
| Operating Income | -51.33% | -50.06% | |||
| Income Before Tax | -50.94% | -56.05% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -50.94% | -56.05% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -50.94% | -56.05% | |||
| EBIT | -51.33% | -50.06% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -47.22% | 18.18% | |||
| Normalized Basic EPS | -43.48% | 14.81% | |||
| EPS Diluted | -47.22% | 18.18% | |||
| Normalized Diluted EPS | -43.48% | 14.81% | |||
| Average Basic Shares Outstanding | 3.86% | 88.23% | |||
| Average Diluted Shares Outstanding | 3.86% | 88.23% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||